John Gunselman, DO
Urology · Portland, ORNPI 1194953125
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,972 of the $4,751 with a category attached, or 62.6%. 31 manufacturers reported payments, led by Intuitive Surgical at 31.9% of the total. Reporting peaked in 2023 at $1,394 and has fallen 63.5% since, to $509 in 2025.
Across 105 payments — averaging $45.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Procept Biorobotics Corporation$916
- Astellas Pharma US Inc$444
- Sumitomo Pharma America, Inc.$207
- AbbVie$177
- Dendreon Pharmaceuticals LLC$164
- plus $1K from 25 others
What the payments were for
- Travel & lodging$1,47931%
- Food & beverage$2,97263%
- Education$3016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $1,518 |
| Procept Biorobotics Corporation | 8 | $916 |
| Astellas Pharma US Inc | 14 | $444 |
| Sumitomo Pharma America, Inc. | 3 | $207 |
| AbbVie | 12 | $177 |
| Dendreon Pharmaceuticals LLC | 6 | $164 |
| Pfizer | 7 | $136 |
| Calyxo, Inc. | 2 | $133 |
| Neotract Inc. | 3 | $127 |
| Tolmar, Inc. | 6 | $126 |
| Endo Pharmaceuticals Inc. | 2 | $102 |
| Johnson & Johnson | 3 | $71 |
| Olympus America Inc. | 3 | $66 |
| Olympus Corporation Of The Americas | 1 | $65 |
| Urogen Pharma, Inc. | 2 | $58 |
| Verity Pharmaceuticals Inc. | 2 | $41 |
| Bayer | 2 | $41 |
| Myriad Genetic Laboratories, Inc. | 2 | $40 |
| Laborie Medical Technologies Corp. | 1 | $34 |
| Convatec Inc. | 1 | $32 |
| 180 Medical, Inc. | 1 | $28 |
| Endo USA, Inc. | 1 | $27 |
| Teleflex LLC | 1 | $26 |
| Merck | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Immunitybio, Inc. | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Hollister Incorporated | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Coloplast | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,096
- AquaBeam Robotic System$767
- GEMTESA$155
- DA VINCI SP$141
- UroLift$109
How this compares
$4,751 in reported general payments places this provider in the 75th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 42 | $36,831 |
| MyrbetriqMirabegron | 40 | $33,393 |
| Abiraterone Acetate | 36 | $29,824 |
| Methenamine Hippurate | 38 | $3,406 |
| Tamsulosin Hcl | 166 | $2,264 |
| Trospium Chloride | 29 | $1,778 |
| Finasteride | 89 | $1,332 |
| Testosterone Cypionate | 11 | $1,270 |
| Estradiol | 17 | $934 |
| Potassium Citrate ErPotassium Citrate | 16 | $869 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 27 | $549 |
| Oxybutynin Chloride | 59 | $349 |
| Solifenacin Succinate | 22 | $271 |
| Gabapentin | 33 | $265 |
| Cephalexin | 49 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $207 | $36,83142 claims |
| Astellas Pharma US IncMyrbetriq | $444 | $33,39340 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $18 | $29,82436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 153 urology providers in Oregon.
Other urology in Portland
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
- Ian MetzlerPortland$23K
- Sara Spettel AliyarPortland$21K
- Daniel JanoffPortland$15K
- James BreseePortland$14K
- Stanley MyersPortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.